genOway Société anonyme (ALGEN.PA)
EUR 3.92
(0.0%)
EUR 3.92
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.23 Million EUR | -20.04% |
| 2022 | 9.04 Million EUR | -16.44% |
| 2021 | 10.82 Million EUR | 0.56% |
| 2020 | 10.76 Million EUR | 78.97% |
| 2019 | 6.01 Million EUR | 28.88% |
| 2018 | 4.66 Million EUR | 24.7% |
| 2017 | 3.74 Million EUR | 34962.52% |
| 2016 | 10.67 Thousand EUR | -13.58% |
| 2015 | 12.35 Thousand EUR | -93.99% |
| 2014 | 205.52 Thousand EUR | 3160.23% |
| 2013 | 6304.00 EUR | -83.46% |
| 2012 | 38.11 Thousand EUR | 761.64% |
| 2011 | 4424.00 EUR | -42.03% |
| 2010 | 7632.00 EUR | 62.94% |
| 2009 | 4684.00 EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q4 | 7.23 Million EUR | 0.0% |
| 2023 Q2 | 8.13 Million EUR | 0.0% |
| 2023 FY | 7.23 Million EUR | -20.04% |
| 2022 Q4 | 9.04 Million EUR | 0.0% |
| 2022 Q2 | 9.93 Million EUR | 0.0% |
| 2022 FY | 9.04 Million EUR | -16.44% |
| 2021 Q2 | 9.38 Million EUR | 0.0% |
| 2021 FY | 10.82 Million EUR | 0.56% |
| 2021 Q4 | 10.82 Million EUR | 0.0% |
| 2020 Q2 | 10.95 Million EUR | 0.0% |
| 2020 Q4 | 10.76 Million EUR | 0.0% |
| 2020 FY | 10.76 Million EUR | 78.97% |
| 2019 Q2 | 6.38 Million EUR | 0.0% |
| 2019 Q4 | 6.01 Million EUR | 0.0% |
| 2019 FY | 6.01 Million EUR | 28.88% |
| 2018 Q2 | 4.77 Million EUR | 0.0% |
| 2018 FY | 4.66 Million EUR | 24.7% |
| 2018 Q4 | 4.66 Million EUR | 0.0% |
| 2017 Q4 | 3.74 Million EUR | 0.0% |
| 2017 Q2 | 3.59 Million EUR | 0.0% |
| 2017 FY | 3.74 Million EUR | 34962.52% |
| 2016 Q4 | 10.67 Thousand EUR | 0.0% |
| 2016 Q2 | 10.7 Thousand EUR | 0.0% |
| 2016 FY | 10.67 Thousand EUR | -13.58% |
| 2015 FY | 12.35 Thousand EUR | -93.99% |
| 2015 Q2 | 9793.00 EUR | 0.0% |
| 2015 Q4 | 12.35 Thousand EUR | 0.0% |
| 2014 Q4 | 205.52 Thousand EUR | 0.0% |
| 2014 Q2 | 71.07 Thousand EUR | 0.0% |
| 2014 FY | 205.52 Thousand EUR | 3160.23% |
| 2013 Q2 | 7527.00 EUR | 0.0% |
| 2013 Q4 | 6304.00 EUR | 0.0% |
| 2013 FY | 6304.00 EUR | -83.46% |
| 2012 FY | 38.11 Thousand EUR | 761.64% |
| 2012 Q4 | 38.11 Thousand EUR | 0.0% |
| 2012 Q2 | 5510.00 EUR | 0.0% |
| 2011 FY | 4424.00 EUR | -42.03% |
| 2011 Q4 | 4424.00 EUR | 0.0% |
| 2011 Q2 | 5765.00 EUR | 0.0% |
| 2010 FY | 7632.00 EUR | 62.94% |
| 2010 Q4 | 7632.00 EUR | 0.0% |
| 2010 Q2 | 7299.00 EUR | 0.0% |
| 2009 Q4 | 4684.00 EUR | 0.0% |
| 2009 Q2 | 41.66 Thousand EUR | 0.0% |
| 2009 FY | 4684.00 EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -113.375% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 86.958% |
| Adocia SA | 13.08 Million EUR | 44.733% |
| Aelis Farma SA | 4.03 Million EUR | -79.133% |
| Biophytis S.A. | 8.27 Million EUR | 12.534% |
| Advicenne S.A. | 17.42 Million EUR | 58.488% |
| IntegraGen SA | 1.12 Million EUR | -543.121% |
| Medesis Pharma S.A. | 1.2 Million EUR | -502.784% |
| Neovacs S.A. | 650 Thousand EUR | -1012.831% |
| NFL Biosciences SA | 62.17 Thousand EUR | -11534.128% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -66.037% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -166.243% |
| Sensorion SA | 2.86 Million EUR | -152.142% |
| Theranexus Société Anonyme | 3.64 Million EUR | -98.555% |
| TME Pharma N.V. | 1.16 Million EUR | -520.36% |
| Valbiotis SA | 6.87 Million EUR | -5.167% |
| TheraVet SA | 1.15 Million EUR | -523.641% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 19.611% |
| argenx SE | 18.1 Million EUR | 60.048% |
| BioSenic S.A. | 28.16 Million EUR | 74.314% |
| Celyad Oncology SA | 902 Thousand EUR | -701.929% |
| DBV Technologies S.A. | 13.01 Million USD | 44.438% |
| Galapagos NV | 9.59 Million EUR | 24.621% |
| Genfit S.A. | 70.17 Million EUR | 89.693% |
| GeNeuro SA | 7.73 Million EUR | 6.519% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -36.634% |
| Innate Pharma S.A. | 39.89 Million EUR | 81.868% |
| Inventiva S.A. | 37.4 Million EUR | 80.663% |
| MaaT Pharma SA | 14.07 Million EUR | 48.608% |
| MedinCell S.A. | 58.96 Million EUR | 87.732% |
| Nanobiotix S.A. | 50.56 Million EUR | 85.695% |
| Onward Medical N.V. | 16.87 Million EUR | 57.133% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 47.152% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 84.207% |
| Oxurion NV | 12.33 Million EUR | 41.354% |
| Pharming Group N.V. | 155.29 Million EUR | 95.342% |
| Poxel S.A. | 46.9 Million EUR | 84.577% |
| GenSight Biologics S.A. | 18.42 Million EUR | 60.748% |
| Transgene SA | 1.25 Million EUR | -475.45% |
| Financière de Tubize SA | 79.2 Million EUR | 90.867% |
| UCB SA | 3.03 Billion EUR | 99.762% |
| Valneva SE | 208.81 Million EUR | 96.536% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -18935.271% |